Trevi Therapeutics (TRVI) Cash from Financing Activities (2018 - 2026)

Trevi Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $222000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 97.45% year-over-year to $222000.0 in Q1 2026; TTM through Mar 2026 was $112.5 million, a 60.26% increase from a year earlier, with the FY2025 full-year figure at $121.0 million, up 96.82% from the prior year.
• Cash from Financing Activities declined to $222000.0 in Q1 2026 per TRVI's latest filing, from $284000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $110.4 million in Q2 2025 and bottomed at -$7.7 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is $1.5 million (2023), against an average of $16.8 million.
• Across the five-year window, Cash from Financing Activities tumbled 172.48% in 2023 and jumped 95409.26% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $652000.0 in 2022, then tumbled by 108.28% to -$54000.0 in 2023, then soared by 95409.26% to $51.5 million in 2024, then plunged by 99.45% to $284000.0 in 2025, then decreased by 21.83% to $222000.0 in 2026.
• Per Business Quant, the three latest TRVI Cash from Financing Activities figures stand at $222000.0 (Q1 2026), $284000.0 (Q4 2025), and $1.6 million (Q3 2025).